Suppr超能文献

[地中海贫血(或小红细胞血症)的临床方面]

[Clinical aspects of thalassemia (or microcythemia)].

作者信息

Bianco I

出版信息

Minerva Med. 1981 Nov 3;72(43):2865-82.

PMID:7301167
Abstract

The thalassaemias are genetic syndromes brought about by a low or nil synthesis of one or more of the main globinic chains and by consequent imbalance of the normal ratio between alpha and non-alpha chains. Three basic pictures can be distinguished: (1) microcythemia or thalassaemia minima, the expression of heterozygosis for one microcythemic gene, which includes beta, delta beta and alpha microcythemias. Subjects are healthy but very often pale and asthenic, (2) intermediate thalassaemia, very similar to thalassaemia major, though a less severe disease. It is the expression of the presence of microythemic geness which results in a globin synthesis imbalance less marked than that of the thalassaemia major. The patients are frankly anemic and more or less pronounced hyperhemolysis (but they only need sporadic transfusions, usually at adult age), and present splenomegaly often of a considerable extent and hepatomegaly. Their physical growth and reproductive capacity are normal or nearly so and they attain the fifth or sixth decade of life. Two varieties of this syndrome have been identified, namely beta-intermediate thalassaemias (or Rietti-Greppi-Micheli's disease or also constitutional microcythemic anemia) and alpha-intermediate thalassaemias (or Hb H disease); (3) thalassaemia major or Cooley's anemia or Mediterranean anemia, the expression of homozygosis for severe genes of microcythemia which results in a marked globin synthesis imbalance; this is a so severe disease that not treated patients usually die when they are three-four years old. Nowadays, however, prognosis, clinical course and life expectancy of these patients are considerably improved so that they usually attain the third decade of age in relatively fair conditions. There are available three fundamental therapeutic actions: blood transfusions carried out at very short intervals; splenectomy which allows to reduce the rhythm of the blood transfusion regimen; the iron chelating therapy which delays the onset of the iron overloading in the organism. Finally, it is possible the prevention of this disease by preventing the procreation between microcythemics and by prenatal identification of Cooley's foetuses followed by thier selective abortion.

摘要

地中海贫血是一类遗传性综合征,由一条或多条主要珠蛋白链合成减少或缺失,以及由此导致的α链与非α链正常比例失衡引起。可区分出三种基本情况:(1)小红细胞症或极轻型地中海贫血,是一个小红细胞症基因杂合子的表现形式,包括β、δβ和α型小红细胞症。患者身体健康,但常面色苍白、身体虚弱;(2)中间型地中海贫血,与重型地中海贫血非常相似,不过病情较轻。它是存在小红细胞症基因的表现,导致珠蛋白合成失衡程度比重型地中海贫血轻。患者明显贫血,或多或少有明显的高溶血现象(但通常仅在成年期需要偶尔输血),常出现程度相当大的脾肿大和肝肿大。他们的身体生长和生殖能力正常或接近正常,能活到五六十岁。已确定该综合征有两个变种,即β中间型地中海贫血(或里蒂-格雷皮-米凯利病,或也称为体质性小红细胞贫血)和α中间型地中海贫血(或血红蛋白H病);(3)重型地中海贫血或库利贫血或地中海贫血,是严重小红细胞症基因纯合子的表现,导致明显的珠蛋白合成失衡;这是一种非常严重的疾病,未经治疗的患者通常在三四岁时死亡。然而,如今这些患者的预后、临床病程和预期寿命有了显著改善,以至于他们通常能在相对良好的状况下活到三十岁左右。有三种基本治疗方法:每隔很短时间进行输血;脾切除术可减少输血疗程的频率;铁螯合疗法可延缓机体铁过载的发生。最后,通过防止小红细胞症患者之间生育以及产前鉴定库利胎儿并进行选择性流产,有可能预防这种疾病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验